Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Triple-negative breast cancer (TNBC) lacks effective targeted therapies.
• Chimeric antigen receptor (CAR) natural killer (NK) cells are an emerging cancer treatment modality.
• CD44v6 is identified as a potential therapeutic target in TNBC.

Purpose of the Study:

• To develop and evaluate a novel CAR-NK cell therapy targeting CD44v6 for TNBC.
• To engineer CAR-NK cells with enhanced anti-tumor activity and resistance to the tumor microenvironment (TME).

Main Methods:

• Development of a next-generation CAR targeting CD44v6, incorporating IL-15 superagonist and checkpoint inhibitor functionalities.
• Assessment of CD44v6 CAR-NK cell cytotoxicity against TNBC using 3D spheroid models.
• Evaluation of the role of IL-15 superagonist release and PD-1/PD-1 ligand interaction in therapeutic efficacy.

Main Results:

• CD44v6 CAR-NK cells exhibited potent cytotoxicity against TNBC in 3D models.
• IL-15 superagonist release was triggered by CD44v6 recognition, enhancing cytotoxic attack.
• Engineered CAR-NK cells demonstrated resistance to PD-1 ligand-mediated immunosuppression within the TME.

Conclusions:

• CD44v6 CAR-NK cells represent a promising therapeutic strategy for TNBC.
• This approach overcomes TME-induced immunosuppression, offering a novel treatment option for breast cancer (BC).